Refractory Malignant Neoplasm Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0074899 (Refractory Malignant Neoplasm)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03439085DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersTreatment